Judith M. Bliss
Statistician who ran the START, FAST-Forward and POETIC trials that reshaped breast cancer radiotherapy and endocrine therapy.
Overview
Judith Bliss directs the ICR Clinical Trials and Statistics Unit, which ran the UK START and FAST-Forward hypofractionation trials, IMPORT LOW and HIGH, POETIC and PERSEPHONE among many others, making it one of the most productive academic trial units in oncology. She has led methodological work on non-inferiority designs and long-term follow-up and is a senior author on most UK breast radiotherapy trials.
Pages like this
not linked directly; found by shared links- PersonA. Murray Brunt
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags breast, radiotherapy.
- PersonTimothy J. Whelan
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags breast, radiotherapy.
- PersonCharlotte E. Coles
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags breast, radiotherapy.
- PersonRichard Gray
Shares HR-positive / HER2-negative breast cancer and the tags biostatistics, breast.
- PersonHelena Earl
Shares PERSEPHONE and the tag breast.
- PersonMitch Dowsett
Shares The Institute of Cancer Research, HR-positive / HER2-negative breast cancer and the tag breast.
- PersonStephen Johnston
Shares The Institute of Cancer Research, HR-positive / HER2-negative breast cancer and the tag breast.
- IdeaUse a polygenic risk score to set when screening starts
Shares The Institute of Cancer Research, HR-positive / HER2-negative breast cancer.